Lotus Pharmaceutical Co Ltd (1795) fair value: what the stock is really worth
As of Nov 6, 2026: fair value (intrinsic value) of Lotus Pharmaceutical Co Ltd stock TWD 210, price TWD 166, upside +26.3%, quality 39 out of 100. Rating: undervalued. Calculated from audited financials with 24 of our 26 valuation models and 37 quality factors, updated daily.
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 3, 2026.
How to read this chart
60‑month range 80.20 TWD – 363.00 TWD · fair‑value band 105.57 TWD – 425.34 TWD · the 166.00 TWD price screens below the 209.63 TWD fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 3, 2026.
Follow Lotus Pharmaceutical Co in your weekly email
Every Wednesday you see whether Lotus Pharmaceutical Co is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Lotus Pharmaceutical Co., Ltd. engages in the research and development, manufacture, and sale of generic pharmaceutical products in Taiwan, South Korea, the United States, and internationally.
Show moreShow less
Its product portfolio focuses on generics in the fields of oncology, central nervous system, cardiovascular diseases, woman health, and anti-obesity.
The company also engages in retail of clinical machines; biotech technological consulting services; sale of pharmaceuticals and medicinal chemical products; marketing activities; market planning and business information services; and consultancy services on health management, health technology, and trading information services.
In addition, it offers management consultancy services; pharmaceutical regulatory affairs project management, and data collection and agency services; healthcare consultancy services and operates as a contract research organization.
Lotus Pharmaceutical Co., Ltd. was incorporated in 1966 and is headquartered in Taipei City, Taiwan.
Stock analysis
Lotus Pharmaceutical Co Ltd (1795) currently trades at 166.00 TWD, while our model-based Fair Value estimate is 209.63 TWD, implying the stock looks roughly 21% undervalued today.
Show more
Valuation
Bull case: the Growth Earnings group reads highest at a median of 531.03 TWD per share, and 18 of the 24 models we run sit above the 166.00 TWD price.
Bear case: the Dividend Discount group reads lowest at 78.55 TWD, and 6 of the 24 models stay below the price. Data coverage for this calculation is high.
Scenario range: 105.57 TWD (bear) to 425.34 TWD (bull), the price of 166.00 TWD sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 39/100 (below-average quality), in the Healthcare sector.
Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Lotus Pharmaceutical Co Ltd reported revenue of 20.5B TWD in FY2025 versus 12.6B TWD in FY2021, a compound +12.8%/yr. Reported net income was 4.7B TWD in FY2025, compounding +35.4%/yr from FY2021.
Key figures
Market cap 43.4B TWD (≈ $1.3B) Small · P/E ratio 11.7 · P/S ratio 1.52 · EPS (TTM) 14.22 TWD · Dividend yield 1.5% · Net margin 13.2% · Return on equity 16.9% · Return on assets (EBIT) 12.1% (5-year average).
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 60 out of 100 (low confidence).
What moves the price
The share trades about 54% below its 52-week high and 4% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −27% fair-value upside, at 26%, 1795 screens cheaper than that median.
Fair Value models
Bear105.57 TWDFair Value 209.63 TWDBull425.34 TWD
Price 166.00 TWD · Upside +26.3%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Based on fiscal year 2025 figures (about 10 months old). Earnings retained since then (10.02 TWD per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.62/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Revenue growth 1 year
+10.4%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+11.9%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+13.8%
Start year 2020 (pandemic). Over 10 years: +14.0% a year
Revenue growth 16 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+24.6%
’14
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
What shareholders gained per year (last 5 years), in TWD ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Measured in TWD: this currency has depreciated against the euro and dollar over the long run, so part of the nominal rate is currency erosion that never reaches a EUR/USD investor.
+35.2%
Earnings growth per share plus dividend.
Earnings per share, growth per year+33.7%
Dividend (yield on the price)1.5%
Pace: 5 vs 10 years ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.33.7% vs 45.1%, slowing
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.15% → 29%
Pace: the 5-year rate starts in 2020 (pandemic)
Growth Forecast
Little optimism in the price
The price assumes more growth than the company has delivered so far and less than analysts expect.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+17.4%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect ⓘAnalysts publish sales forecasts for the next two fiscal years. For the years after that, growth slows evenly to 2 % a year by year ten (2 % is the long-run rate our models use). Projected years are marked as such.
+22.7%
Yearly sales growth analysts expect, extended to five years.
After inflation (Taiwan: IMF forecast 1.6% a year to 2030, 1.5% from 2016 to 2025) that is about +15.6% a year for the price and +20.8% for the forecasts.
Compare Lotus Pharmaceutical Co Ltd with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Drug Manufacturers - Specialty & Generic · 549 stocks
Beats the industry median on 10/13 measures
Overall it ranks above its industry peers.
Valuation
Quality Score39 · Bottom 25%
Fair Value upside+26.3% · Top 25%
Profitability
Return on equity (12 months)16.9% · Top 25%
Return on assets4.5% · Above median
Net margin (12 months)13.2% · Above median
Operating margin (12 months)26.5% · Top 25%
Growth and dividend
Revenue growth (quarter YoY)85.6% · Top 25%
Dividend yield (12 months)1.5% · Below median
Balance sheet
Debt / equity1.79× · Highest 25%
Valuation Multiplesvs Drug Manufacturers - Specialty & Generic median · lower = cheaper
P/E (12 months)11.7× · Cheapest 25%
P/B1.82× · book value is mostly goodwill ⓘGoodwill and other intangible assets are larger than the equity. The book value mainly reflects prices paid for past acquisitions, so we do not rank this P/B against the peer group.
P/S (12 months)1.52× · Cheaper than median
Price / free cash flow (fiscal year)13.9× · Cheaper than median
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Lotus Pharmaceutical Co Ltd Fair Value". https://www.fairvalue-calculator.com/stock/1795
Frequently asked questions
Is Lotus Pharmaceutical Co Ltd (1795) overvalued or undervalued?
As of Nov 3, 2026, our model estimates a fair value of 209.63 TWD versus a price of 166.00 TWD, about +26% upside (undervalued).
What is the fair value of 1795?
Our model-based fair value for Lotus Pharmaceutical Co Ltd is 209.63 TWD (as of Nov 3, 2026), built from audited fundamentals. The current price: 166.00 TWD.
What is the quality score of 1795?
Lotus Pharmaceutical Co Ltd has a Quality Score of 39/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Lotus Pharmaceutical Co Ltd (1795)?
Our model-based price target is the fair value of 209.63 TWD (as of Nov 3, 2026) from 24 valuation models. Cautious scenario 105.57 TWD, optimistic scenario 425.34 TWD. It is a calculation from audited fundamentals, not an analyst target.
What is the Lotus Pharmaceutical Co Ltd stock forecast for 2026?
Our models put fair value at 209.63 TWD, about +26% upside versus a price of 166.00 TWD (undervalued). Cautious scenario 105.57 TWD, optimistic scenario 425.34 TWD. The calculation is refreshed regularly with new filings.
What is the revenue of Lotus Pharmaceutical Co Ltd (1795)?
Lotus Pharmaceutical Co Ltd reported trailing-twelve-month revenue of about 28.5B TWD (latest available figure, as of Nov 3, 2026).
Does Lotus Pharmaceutical Co Ltd pay a dividend?
Lotus Pharmaceutical Co Ltd currently shows a dividend yield of 1.53% relative to its recent price (as of Nov 3, 2026).
How much is the dividend of Lotus Pharmaceutical Co Ltd (1795) and when is the ex-dividend date?
Lotus Pharmaceutical Co Ltd pays a dividend of 2.53 TWD per share a year, a dividend yield of 1.5%. The last ex-dividend date was Aug 31, 2026. The payout ratio is 17.8% of earnings. Free cash flow covers the dividend 4.64 times. Our assessment: Well covered. A low payout and the dividend is fully funded by free cash flow, a comfortable, sustainable dividend.
What growth is priced into Lotus Pharmaceutical Co Ltd (1795)?
For today's price to be fair in a discounted-cash-flow model, Lotus Pharmaceutical Co Ltd would have to grow free cash flow by +17.4 % per year for five years (discount rate 10.8 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +13.8 % per year. As of Nov 3, 2026.
What discount rate (WACC) does the fair value of 1795 use?
Our models discount Lotus Pharmaceutical Co Ltd at 10.8 %: a base by market capitalisation (small), damped by beta 0.66, country premium for Taiwan. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Lotus Pharmaceutical Co Ltd that is +17.4 % per year for five years, then slowing evenly to 2 % by year ten, using the same discount rate (10.8 %) and the same formula as our fair value.
How much growth has Lotus Pharmaceutical Co Ltd (1795) delivered so far?
Over the past 5 years revenue at Lotus Pharmaceutical Co Ltd grew +13.8 % a year. The price currently implies free-cash-flow growth of +17.4 % per year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Lotus Pharmaceutical Co Ltd (1795) growing?
The median revenue growth in the sector is +6.2 % a year. That is the yardstick for the growth priced into Lotus Pharmaceutical Co Ltd (+17.4 % per year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Lotus Pharmaceutical Co Ltd (1795)?
The free-cash-flow yield on the price is 7.21 %: that much free cash flow Lotus Pharmaceutical Co Ltd produces per unit of market value. When it exceeds the discount rate of our models (10.8 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Lotus Pharmaceutical Co Ltd (1795)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Lotus Pharmaceutical Co Ltd it is 209.63 TWD per share (as of Nov 3, 2026), against a price of 166.00 TWD. It is the blended result of 24 valuation models in 7 families (DCF Models, Earnings-Based, Dividend Discount, Multiples, Growth DCF, Economic Profit, Growth Earnings).
Is Lotus Pharmaceutical Co Ltd stock overvalued or undervalued in 2026?
As of Nov 3, 2026, 1795 trades below its calculated fair value: price 166.00 TWD, fair value 209.63 TWD, a gap of about +26% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 1795?
No. The price is what the market pays today (166.00 TWD); the fair value is what the company's own numbers justify (209.63 TWD). For Lotus Pharmaceutical Co Ltd the two are 43.63 TWD per share apart. That gap is exactly why we show both numbers side by side.
How much is Lotus Pharmaceutical Co Ltd worth?
The market values Lotus Pharmaceutical Co Ltd at about 43.4B TWD (market capitalisation, as of Nov 3, 2026). Per share that is 166.00 TWD; our models calculate a fair value of 209.63 TWD per share.
What do the bullish and bearish scenarios say about 1795?
Our models span a range for Lotus Pharmaceutical Co Ltd: cautious scenario 105.57 TWD, base 209.63 TWD, optimistic 425.34 TWD per share (as of Nov 3, 2026, price 166.00 TWD). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of 1795?
Lotus Pharmaceutical Co Ltd trades at a price-to-earnings ratio of 11.7 (as of Nov 3, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of 209.63 TWD is built from several models across several years. Other multiples: P/B 1.8, P/S 1.5, EV/EBITDA 8.5.
How solid is the balance sheet of Lotus Pharmaceutical Co Ltd (1795)?
Balance-sheet figures for Lotus Pharmaceutical Co Ltd (as of Nov 3, 2026): return on equity 16.9%, debt of 1.79 per unit of equity. They feed the Quality Score of 39/100, which measures business quality independently of the share price.
How far is 1795 from its 52-week high?
Lotus Pharmaceutical Co Ltd trades at 166.00 TWD, about 54% below its 52-week high of 363.00 TWD and 4% above the low of 159.00 TWD (as of Nov 6, 2026). Distance from the high says nothing about value: that is what the fair value of 209.63 TWD is for.
Which stocks are comparable to Lotus Pharmaceutical Co Ltd?
From the same area (Healthcare) we also value Merck KGaA, Takeda Pharmaceutical Company, Galderma Group, Teva Pharmaceutical Industries Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Lotus Pharmaceutical Co Ltd stock attractive at the current price?
The data as of Nov 3, 2026: price 166.00 TWD, calculated fair value 209.63 TWD (+26%), Quality Score 39/100, from 24 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 1795 calculated?
We run Lotus Pharmaceutical Co Ltd through 24 models from 7 families: DCF Models, Earnings-Based, Dividend Discount, Multiples, Growth DCF, Economic Profit, Growth Earnings. Every model gets the same audited fundamentals; the fair value of 209.63 TWD builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.3% above its aggregate fair value. Lotus Pharmaceutical Co Ltd currently trades 21% below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Lotus Pharmaceutical Co Ltd (1795)?
The closing price on Nov 6, 2026 was 166.00 TWD. Our model-based fair value is 209.63 TWD, about +26% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Lotus Pharmaceutical Co Ltd right now?
The model range is unusually wide (105.57 TWD to 425.34 TWD). The outcome hinges heavily on assumptions, so read the point estimate with caution. The price sits in the lower half of our model range, the side with the larger margin of safety. The data supports the verdict: every model runs on fully documented inputs.
Key figures of Lotus Pharmaceutical Co Ltd
How large is the market capitalisation of Lotus Pharmaceutical Co Ltd (1795)?
The market capitalisation of Lotus Pharmaceutical Co Ltd is 43.4B TWD (≈ $1.3B). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Lotus Pharmaceutical Co Ltd (1795)?
The price-to-sales ratio of Lotus Pharmaceutical Co Ltd is 1.52 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Lotus Pharmaceutical Co Ltd (1795)?
Earnings per share at Lotus Pharmaceutical Co Ltd are 14.22 TWD (price ÷ EPS = P/E 11.7). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Lotus Pharmaceutical Co Ltd (1795)?
The dividend yield of Lotus Pharmaceutical Co Ltd is 1.5% (payout 17.8%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Lotus Pharmaceutical Co Ltd (1795)?
The net margin of Lotus Pharmaceutical Co Ltd is 13.2% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Lotus Pharmaceutical Co Ltd (1795)?
The return on equity (ROE) of Lotus Pharmaceutical Co Ltd is 16.9% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Lotus Pharmaceutical Co Ltd (1795)?
On an EBIT basis the return on assets of Lotus Pharmaceutical Co Ltd is 12.1% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Lotus Pharmaceutical Co Ltd (1795)?
The operating margin of Lotus Pharmaceutical Co Ltd is 26.5% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Lotus Pharmaceutical Co Ltd (1795)?
Revenue at Lotus Pharmaceutical Co Ltd is growing +85.6% versus a year earlier (3y avg +11.9%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Lotus Pharmaceutical Co Ltd (1795)?
Earnings per share at Lotus Pharmaceutical Co Ltd are growing −11.8% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net debt does Lotus Pharmaceutical Co Ltd (1795) carry?
The net debt of Lotus Pharmaceutical Co Ltd is 48.2B TWD (fiscal year 2025, ≈ 15.4 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Lotus Pharmaceutical Co Ltd in the live analysis
One click puts Lotus Pharmaceutical Co Ltd on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Broad data
Nov 3, 2026